Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 6/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.38 |
| ▸ | PARG | Q86W56 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15917702 | 0.86 | PDE3B (0.78) | PDE3BPDE3AALDH1A1MAOB | |
| SCHEMBL15917986 | 0.85 | PDE3B (0.80) | PDE3BPDE3AALDH1A1 | |
| SCHEMBL15917778 | 0.85 | PDE3B (0.80) | PDE3BPDE3AALDH1A1MAOBDAO | |
| SCHEMBL15917628 | 0.84 | PDE3B (1.00) | PDE3BPDE3AALDH1A1 | |
| SCHEMBL15917729 | 0.84 | PDE3B (1.00) | PDE3BPDE3AALDH1A1MAOB | |
| SCHEMBL15918716 | 0.81 | PDE3B (0.77) | PDE3BPDE3AALDH1A1 | |
| SCHEMBL15918461 | 0.81 | PDE3B (0.74) | PDE3BPDE3AALDH1A1MAOBDAO | |
| SCHEMBL15917791 | 0.80 | PDE3B (0.72) | PDE3BPDE3AALDH1A1DAOPARG | |
| SCHEMBL15917811 | 0.80 | PDE3B (0.46) | PDE3BPDE3AALDH1A1MAOBDAO | |
| SCHEMBL15917623 | 0.79 | PDE3B (1.00) | PDE3BPDE3AALDH1A1MAOBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242982-B2 | Pyridopyrimidine based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-26 | — | — | US | claimed |
| US-20140221651-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-07 | — | — | US | claimed |
| US-9505760-B2 | Pyridopyrimidine based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-11-29 | — | — | US | disclosed |
| US-9505760-B2 | Pyridopyrimidine based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-11-29 | — | — | US | disclosed |
| US-9505760-B2 | Pyridopyrimidine based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-11-29 | — | — | US | disclosed |
| US-20160194319-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-07-07 | — | — | US | disclosed |
| US-20160194319-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-07-07 | — | — | US | disclosed |
| US-20160194319-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-07-07 | — | — | US | disclosed |
| US-9242982-B2 | Pyridopyrimidine based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-26 | — | — | US | disclosed |
| US-9242982-B2 | Pyridopyrimidine based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-26 | — | — | US | disclosed |
| US-9242982-B2 | Pyridopyrimidine based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-26 | — | — | US | disclosed |
| US-20140221651-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-07 | — | — | US | disclosed |
| US-20140221651-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-07 | — | — | US | disclosed |
| US-20140221651-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221651-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | PDE3A, PDE3B, PDE5A | PDE3B 2/4885PDE3A 1/4885ALDH1A1 225/4885 |
| US-20160194319-A1 | PYRIDOPYRIMIDINE BASED DERIVATIVES AS POTENTIAL PHOSPHODIESTERASE 3 (PDE3) INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | PDE3A, PDE3B, PDE5A | PDE3B 2/4885PDE3A 1/4885ALDH1A1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.